PDF(Pubmed)
Abstract：
UNASSIGNED: To prevent chronic brucellosis, this study analysed the changes in patient antibody titers, and the trajectories of biochemical indicators at different stages of brucellosis, identified relevant biomarkers, and explored risk factors affecting the prognosis of brucellosis patients.
UNASSIGNED: A prospective cohort study was conducted to follow 100 patients with acute brucellosis. Laboratory serological test results [taken with a serum (tube) agglutination test (SAT)] and biochemical parameters (liver function, renal function, and hematological system) were measured repeatedly at four-time points: 0 weeks-baseline survey, 6 weeks after the first treatment, 12 weeks after the second treatment, and 3 months after the third treatment. The changes in the antibody titres and biochemical parameters at each time point were analysed for trend changes.
UNASSIGNED: One hundred patients with acute brucellosis were enrolled in this follow-up study, with 100% retention in follow-up. By the third follow-up, 21 patients had turned subacute and 11 had turned chronic. One-way repeated measures analysis of variance results showed statistically significant differences (p < 0.01) across the time points for the following five indicators: alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine (SCr) and platelet count. The clinical symptoms of patients in the acute stage were mainly joint pain, fatigue, and fever, while those in the chronic stage complained primarily of joint pain and fatigue. The results of multivariate logistic analysis showed that joint pain [odds ratio (OR) = 3.652, 95% confidence interval (CI) =1.379-9.672], monoarticular pain (OR = 6.356, 95% CI = 4.660-8.669), elevated SCr (OR = 15.804, 95% CI = 1.644-151.966) and elevated haemoglobin (Hb) (OR = 1.219, 95% CI = 1.065-1.736) were risk factors for poor prognosis (not cured or chronic) in patients with brucellosis.
UNASSIGNED: The trajectory of changes in patient SAT posirates and antibody titers can be used to distinguish patients with chronic brucellosis. The brucellosis is preventable and treatable, and the standard treatment can be effective in reducing the clinical symptoms of affected patients. If patients are not treated in a timely manner, joint pain, monoarticular pain, and elevated SCr are risk factors for patients who are not cured. Therefore, the treatment cycle for these patients should be extended.
UNASSIGNED: A prospective cohort study was conducted to follow 100 patients with acute brucellosis. Laboratory serological test results [taken with a serum (tube) agglutination test (SAT)] and biochemical parameters (liver function, renal function, and hematological system) were measured repeatedly at four-time points: 0 weeks-baseline survey, 6 weeks after the first treatment, 12 weeks after the second treatment, and 3 months after the third treatment. The changes in the antibody titres and biochemical parameters at each time point were analysed for trend changes.
UNASSIGNED: One hundred patients with acute brucellosis were enrolled in this follow-up study, with 100% retention in follow-up. By the third follow-up, 21 patients had turned subacute and 11 had turned chronic. One-way repeated measures analysis of variance results showed statistically significant differences (p < 0.01) across the time points for the following five indicators: alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine (SCr) and platelet count. The clinical symptoms of patients in the acute stage were mainly joint pain, fatigue, and fever, while those in the chronic stage complained primarily of joint pain and fatigue. The results of multivariate logistic analysis showed that joint pain [odds ratio (OR) = 3.652, 95% confidence interval (CI) =1.379-9.672], monoarticular pain (OR = 6.356, 95% CI = 4.660-8.669), elevated SCr (OR = 15.804, 95% CI = 1.644-151.966) and elevated haemoglobin (Hb) (OR = 1.219, 95% CI = 1.065-1.736) were risk factors for poor prognosis (not cured or chronic) in patients with brucellosis.
UNASSIGNED: The trajectory of changes in patient SAT posirates and antibody titers can be used to distinguish patients with chronic brucellosis. The brucellosis is preventable and treatable, and the standard treatment can be effective in reducing the clinical symptoms of affected patients. If patients are not treated in a timely manner, joint pain, monoarticular pain, and elevated SCr are risk factors for patients who are not cured. Therefore, the treatment cycle for these patients should be extended.
摘要：
■为了预防慢性布鲁氏菌病，这项研究分析了患者抗体滴度的变化，以及布鲁氏菌病不同阶段生化指标的轨迹，确定了相关的生物标志物，探讨影响布鲁氏菌病患者预后的危险因素。
■对100例急性布鲁氏菌病患者进行了前瞻性队列研究。实验室血清学检查结果[采用血清（管）凝集试验（SAT）]和生化指标（肝功能，肾功能,和血液系统）在四个时间点重复测量：0周基线调查，第一次治疗后6周，第二次治疗后12周，第三次治疗后3个月。分析每个时间点的抗体滴度和生化参数的变化的趋势变化。
■这项随访研究纳入了100例急性布鲁氏菌病患者，在随访中保留100%。在第三次后续行动中，21例患者转为亚急性，11例转为慢性。单向重复测量方差分析结果显示，在以下五个指标的时间点之间存在统计学上的显着差异（p<0.01）：丙氨酸转氨酶，天冬氨酸转氨酶,总胆红素,血清肌酐（SCr）和血小板计数。急性期患者的临床症状主要为关节痛,疲劳,发烧，而慢性阶段的患者主要抱怨关节疼痛和疲劳。多因素logistic分析结果显示关节疼痛[比值比(OR)=3.652,95%置信区间(CI)=1.379~9.672],单关节疼痛（OR=6.356，95%CI=4.660-8.669），SCr升高(OR=15.804,95%CI=1.644-151.966)和血红蛋白升高(OR=1.219,95%CI=1.065-1.736)是布鲁氏菌病患者预后不良(未治愈或慢性)的危险因素.
■患者SAT阳性率和抗体滴度的变化轨迹可用于区分患有慢性布鲁氏菌病的患者。布鲁氏菌病是可以预防和治疗的，标准治疗可有效减轻患者的临床症状。如果患者没有得到及时治疗，关节痛,单关节疼痛,SCr升高是未治愈患者的危险因素。因此,这些患者的治疗周期应该延长。
■对100例急性布鲁氏菌病患者进行了前瞻性队列研究。实验室血清学检查结果[采用血清（管）凝集试验（SAT）]和生化指标（肝功能，肾功能,和血液系统）在四个时间点重复测量：0周基线调查，第一次治疗后6周，第二次治疗后12周，第三次治疗后3个月。分析每个时间点的抗体滴度和生化参数的变化的趋势变化。
■这项随访研究纳入了100例急性布鲁氏菌病患者，在随访中保留100%。在第三次后续行动中，21例患者转为亚急性，11例转为慢性。单向重复测量方差分析结果显示，在以下五个指标的时间点之间存在统计学上的显着差异（p<0.01）：丙氨酸转氨酶，天冬氨酸转氨酶,总胆红素,血清肌酐（SCr）和血小板计数。急性期患者的临床症状主要为关节痛,疲劳,发烧，而慢性阶段的患者主要抱怨关节疼痛和疲劳。多因素logistic分析结果显示关节疼痛[比值比(OR)=3.652,95%置信区间(CI)=1.379~9.672],单关节疼痛（OR=6.356，95%CI=4.660-8.669），SCr升高(OR=15.804,95%CI=1.644-151.966)和血红蛋白升高(OR=1.219,95%CI=1.065-1.736)是布鲁氏菌病患者预后不良(未治愈或慢性)的危险因素.
■患者SAT阳性率和抗体滴度的变化轨迹可用于区分患有慢性布鲁氏菌病的患者。布鲁氏菌病是可以预防和治疗的，标准治疗可有效减轻患者的临床症状。如果患者没有得到及时治疗，关节痛,单关节疼痛,SCr升高是未治愈患者的危险因素。因此,这些患者的治疗周期应该延长。
